Public company intelligence preview
CYPHERPUNK TECHNOLOGIES INC
78 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $4.0M average total compensation across covered insiders.
Governance movement
Public aggregate: 2 governance events in the last year.
Institutional ownership
Public aggregate: 39 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
Cypherpunk Technologies Inc. is a Healthcare sector, Biotechnology company based in Massachusetts that now combines a legacy cancer-drug development business with a newer digital asset treasury strategy centered on Zcash (ZEC). Through Leap Therapeutics, it is still developing biomarker-targeted antibody therapies, including sirexatamab (DKN-01) for DKK1-high colorectal cancer and FL-501 for cachexia-related indications. The company remains development-stage with no product revenue and continues to rely on external partners for manufacturing, research, and ecosystem support. Its 2025 results reflect a major strategic pivot, as management shifted capital toward ZEC accumulation and privacy technology while clinical operations were scaled back.
Executive Compensation Practices
In a Biotechnology company like this, executive compensation is typically driven by development milestones, capital-raising execution, regulatory progress, and cost discipline rather than revenue growth. For Cypherpunk, the most relevant performance measures are likely clinical readouts, trial advancement, financing success, cash runway preservation, and the execution of the Zcash treasury strategy, since those were the dominant operational themes in the filings. The sharp reduction in R&D and headcount, along with lower stock-based compensation and incentive pay, suggests pay has likely been influenced by restructuring and tighter spending controls. Because the company is still loss-making and dependent on equity financing, equity awards and milestone-based incentives are especially important in aligning management with long-term value creation.
Insider Trading Considerations
Insider trading patterns in this Healthcare sector, Biotechnology name may be especially sensitive to clinical catalysts, financing events, and major strategic announcements. For a company with no commercial product sales, insider activity often clusters around trial updates, FDA-facing developments, partnership discussions, and capital raises, all of which can materially change valuation. Cypherpunk’s new exposure to ZEC adds another layer of sensitivity, since insider transactions could be influenced by digital asset price volatility, treasury accumulation plans, and regulatory headlines affecting privacy coins. Researchers should also watch for trading blackout periods around clinical data releases, private placements, and accounting-driven events tied to the fair value of digital assets and embedded derivatives.
Unlock the full CYPH insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.